Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions
Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions
The purpose of this research study is to examine the safety of infusing escalated doses of
 allogeneic (from a relative of the patient), enriched natural killer (NK) cells after
 autologous (from the patient) stem cell transplantation. The hypothesis is that the infusion
 of these NK cells early after an autologous stem cell transplant will help to eliminate and
 eradicate any residual cancerous cells that remain in the body and may have survived the
 chemotherapy or radiation.
Natural killer cells are blood cells that are responsible for eliminating cancer cells
 especially when there are only a few. It has been shown that NK cells coming from a
 "mismatched" person (a relative) have a better chance than the patient's own NK cells to
 recognize and kill cancer cells. These cells will be collected from the blood of a parent,
 child or sibling and after preparation in the laboratory, will be given to the patient early
 after an autologous stem cell transplantation like a blood or platelet transfusion. A person
 who has been diagnosed with a blood tumor and received an autologous stem cell transplant has
 the chance of his/her cancer coming back. This study uses NK cells obtained from a relative
 to prevent disease recurrence by potentially eliminating and eradicating any residual
 cancerous cells.
Inclusion Criteria:

 -  Patients who have undergone an autologous stem cell transplant for the following
 diseases:

 -  Acute Myeloid Leukemia

 -  Non-Hodgkin's Lymphoma

 -  Hodgkin's Disease

 -  Multiple Myeloma

 -  Age 13 - 70 years old

 -  Able to give informed consent

 -  Hepatic and renal function: bilirubin less than or equal to 2x normal limits, AST and
 ALT less than or equal to 2x normal limits, serum creatinine less than or equal to
 1.5x normal

 -  ECOG Performance Status less than or equal to 1 (at planned time of transplantation)

 -  Patients with no active infection

 Exclusion Criteria:

 -  Patients who have not recovered sufficiently from the side effects of the autologous
 transplant (i.e. have > grade 2 toxicity in any organ system)

 -  Patients who have insufficient engraftment parameters according to the following
 criteria: WBC < 2,500 /mm3 and platelets < 50,000/mm3

 -  Radiation therapy, chemotherapy, or immunotherapy beginning one week before NK-cell
 infusion and lasting 2 weeks after NK-cell infusion.

 -  Intrinsic impaired organ function (as stated above).

 -  Physical or psychiatric conditions that in the estimation of the PI or designee place
 the patient at high-risk of toxicity or non-compliance.

 -  Uncontrolled, life-threatening infections at the time of infusion.

 -  Concurrent treatment with corticosteroids and/or other immuno-suppressive drugs.